COVID-19 IN HYPERTENSIVE PATIENTS: A REVIEW OF COMORBIDITIES AND WORSE OUTCOMES
Farzan Salehi*, Nidhi Patel, George Sayegh, Febin Prince, Anukul Karn, Anam Hamid, Qingqing Wen, Mahwish Ahmed, Arlette Arraut, Karar Alameedi, Eli C. Garcia Bautista, Nabeel Hussain and Jian M. Garcia Cruz
ABSTRACT
The SARS-CoV-2 virus causes COVID-19, and the first case was reported in Wuhan in late 2019. The virus spreads via direct contact and respiratory droplets. It soon hit different countries, and the World Health Organization declared it a pandemic in early 2020. Most countries around the world started looking for possible pharmacological options against COVID-19. Vaccine trials were started, and countries adopted preventive measures to curb the disease spread. Patients with cardiovascular comorbidities such as hypertension were found to be at an increased risk of serious infections caused by SARS-CoV-2. The association between frequently prescribed hypertensive drugs such as ACE inhibitors/AR blockers, and severe COVID-19 cases have been studied. This review emphasizes the worse outcomes in COVID-19 patients suffering from hypertension and other cardiovascular diseases.
Keywords: .
[Full Text Article]